3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
11
Carcinoma, Non-Small-Cell Lung
7
Pancreatic Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasms
4
Sarcoma
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Lymphoma
2
Liver Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Interventions
aldesleukin
15
Cyclophosphamide
15
fludarabine phosphate
12
fludarabine
11
Interleukin-2
10
Nivolumab
6
Ipilimumab
6
Temozolomide
5
pembrolizumab
3
Fluorouracil
3
trametinib
2
sonidegib
2
dabrafenib
2
binimetinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Sodium Chloride
2
Sirolimus
2
Radiotherapy
2
Radiation
2
Peptides
2
HhAntag691
2
Gefitinib
2
Dacarbazine
2
Cyclosporine
2
Cetuximab
2
Capecitabine
2
veliparib
1
varlilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Skin Neoplasms
×
spartalizumab
×
Clear all
NCT02967692
2025-09-18
COMBI-i
Novartis
Phase 3
Terminated
568 enrolled
28 charts